Combined pharmaceutical composition and application thereof
A combined pharmaceutical composition of compound 1 and docetaxel addresses the limitations of single-drug therapies by achieving a synergistic inhibitory effect on breast cancer cells, enhancing treatment efficacy and overcoming drug resistance.
Patent Information
- Application Number
- CN202310642567.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-31
- Publication Date
- 2024-12-03
AI Technical Summary
Current treatments for breast cancer, particularly those using anthracyclines and taxanes, face challenges such as drug resistance and limited therapeutic efficacy, with existing single-drug therapies showing limited effectiveness against recurrence and metastasis, and compounds like paclitaxel and docetaxel suffer from issues like poor water solubility and toxic side effects.
A combined pharmaceutical composition comprising compound 1 and/or its derivatives, such as Hu7691, combined with docetaxel and/or its derivatives, to achieve a synergistic inhibitory effect on cancer cells, particularly breast cancer cells, utilizing specific molar ratios and dosage forms.
The combined use of compound 1 and docetaxel demonstrates a synergistic effect, significantly enhancing the inhibitory action on cancer cells, offering improved treatment options for breast cancer and potentially other cancers like gastric and ovarian cancer.
Smart Images

Figure CN119055649A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a combined pharmaceutical composition and application thereof. Background Art
[0002] Breast cancer is one of the most common malignant tumors in women. According to statistics, the incidence of breast cancer accounts for 7% to 10% of all malignant tumors in the body, and its incidence among women is second only to uterine cancer. Currently, there are about 1 million breast cancer patients in the world. The incidence of breast cancer has increased by almost 100% in the past 20 years, and the trend of continued growth is still very obvious, posing a huge threat to women's health.
[0003] Anthracyclines and taxanes are commonly used clinically to treat early breast cancer, but 30% of patients still die from recurrence and metastasis, and the average survival period is only 18 to 30 months. The increasingly serious drug resistance brings many difficulties to treatment, and the treatment options are very limited.
[0004] Chinese patent CN108341801A discloses a polyfluorinated substituted aromatic heterocyclic derivative of the following formula, which has a significant inhibitory effect on AKT, and shows strong proliferation inhibition activity on tumor cell lines such as human ovarian cancer cell line (OVCAR-8), human breast cancer cell line (MCF7), human renal cancer cell line (786-O), colon cancer cell line (HCT116), and human myeloma cell line (CEM-C1), and can be used to treat cell proliferation diseases including cancer. Among them, the preferred compound Hu7691 is an ATK targeted tumor inhibitor in the clinical stage, with the structural formula It can act on the PIK3-AKT-mTOR signaling pathway and has certain anti-tumor activity. Docetaxel can inhibit cell division by inhibiting the depolymerization of microtubules and is expected to be used as a chemotherapy drug. The results of the current clinical AKT target inhibitor research show that the drug targeting this target is not effective when used alone and has limited therapeutic effect on tumors.
[0005] Docetaxel (DTX, trade name Taxotere) and Paclitaxel (trade name Taxol) belong to the taxane class and are both FDA-approved anticancer drugs. Among them, the natural product paclitaxel is an effective anticancer compound extracted from the Taxus and Austrotaxus genera of the gymnosperm Taxaceae. In 1994, foreign scholars semi-synthesized docetaxel as a substitute for paclitaxel, and its structural formula is as follows:
[0006]
[0007] Paclitaxel has attracted widespread attention due to its unique anti-cancer mechanism and good anti-cancer effect. However, there are several problems in its use: 1) poor water solubility; 2) multi-drug resistance; 3) certain toxic side effects. In general, taxane compounds have more modifiable sites. Docetaxel was originally developed by Rhone-Poulenc Lean in France. The difference between docetaxel and paclitaxel is that the former has a C3 amino group and a C 10 The tert-butyloxycarbonyl and hydroxyl groups are substituted at the 100-1200 position, respectively, so that the water solubility is slightly greater. It is used as a chemotherapy drug for breast cancer and non-small cell lung cancer. In 1995, docetaxel was first launched in Mexico, South Africa, and Canada as a second-line treatment for advanced breast cancer and non-small cell lung cancer. In May 1996, it was approved by the FDA under the trade name of Taxotere (docetaxel), which is used for the treatment of metastatic breast cancer that has failed chemotherapy and metastatic non-small cell lung cancer that has failed platinum treatment. Subsequently, it was launched in 33 countries including the United Kingdom, the United States, France, Italy, Germany, and Japan. The drug has a wide anti-tumor spectrum and is the most effective single-agent chemotherapy drug for the treatment of metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC) among existing drugs. In recent years, with the continuous development of research, a large number of paclitaxel, docetaxel and their derivatives have been reported and studied. Summary of the invention
[0008] The present invention aims to solve at least one of the above technical problems existing in the prior art. To this end, the present invention provides a pharmaceutical composition which has a good inhibitory effect on breast cancer cells and can be used to effectively treat breast cancer.
[0009] Specifically, the present invention adopts the following technical solutions:
[0010] The first aspect of the present invention is to provide a pharmaceutical composition, which comprises a component A and a component B, wherein the component A is compound 1 and / or its derivatives, wherein R 1 , R 2 and R 3 are independently selected from H, halogen, C 1-6 Alkyl, C 1-6 The B component is paclitaxel or its derivatives, docetaxel or its derivatives, or a combination of the two.
[0011] The pharmaceutical composition according to the first aspect of the present invention has at least the following beneficial effects:
[0012] The tumor inhibitor alone has little inhibitory effect on cancer targets, such as AKT targets. The present invention combines compound 1 and / or its derivatives with docetaxel and / or its derivatives to exert a synergistic effect, which can significantly improve the inhibitory effect on cancer cells.
[0013] In some embodiments of the present invention, the halogen is selected from F, Cl, Br, I; preferably F, Cl, Br.
[0014] In some embodiments of the present invention, the C 1-6 The alkyl group is selected from methyl, ethyl, propyl, isopropyl, butyl and isobutyl; preferably methyl, ethyl and propyl; most preferably methyl.
[0015] In some embodiments of the present invention, the C 1-6 The haloalkyl group is selected from chloromethyl, 1-chloroethyl, 2-chloroethyl, and trifluoromethyl; preferably chloromethyl and trifluoromethyl; most preferably trifluoromethyl.
[0016] In some embodiments of the present invention, the derivatives include any one or more of isomers (including stereoisomers, geometric isomers, tautomers), solvates, metabolites, and pharmaceutically acceptable salts.
[0017] In some embodiments of the present invention, the pharmaceutically acceptable salt of Compound 1 includes any one or more of its L-malate, citrate, phosphate, chloride, nitrate, and sulfate, preferably its L-malate.
[0018] In some embodiments of the present invention, the structural formula of compound 1 is
[0019] In some embodiments of the present invention, in the pharmaceutical composition, component A is and / or its L-malate, namely Component B is docetaxel.
[0020] In some embodiments of the present invention, the molar ratio of component A to component B is 0-10:0-1, preferably 0.001-10:0.0001-0.1, more preferably 0.001-10:0.0001-0.01, further preferably 0.001-10:0.001-0.01.
[0021] In some embodiments of the present invention, the molar ratio of component A to component B is 0.002-4:0.001-0.01, and more preferably 0.002-1.5:0.001-0.01.
[0022] In some embodiments of the present invention, the molar ratio of component A to component B is 0.01-0.02:0.0001-0.00015.
[0023] In some embodiments of the present invention, the molar ratio of component A to component B is 0.1-5:0.0001-0.00015, preferably 0.1-2:0.0001-0.00015, further preferably 0.1-1:0.0001-0.00015, and more preferably 0.1-0.4:0.0001-0.00015.
[0024] In some embodiments of the present invention, the molar ratio of component A to component B is 0.002-10:0.01-0.1, more preferably 0.002-10:0.01-0.05, and most preferably 0.002-10:0.01.
[0025] In some embodiments of the present invention, the unit dose of the A component is 0-100 μM.
[0026] In some embodiments of the present invention, the unit dosage of the B component is 0 to 1000 nM.
[0027] In some embodiments of the present invention, the pharmaceutical composition is a single compound preparation made of component A and component B.
[0028] In some embodiments of the present invention, the dosage form of the pharmaceutical composition is any pharmaceutically acceptable dosage form, preferably tablets, capsules, injections, enemas, emulsions, and the like.
[0029] In some embodiments of the present invention, the pharmaceutical composition may further contain other pharmaceutically active ingredients, and the other pharmaceutically active ingredients do not have adverse reactions with the A component and / or the B component.
[0030] In some embodiments of the present invention, the pharmaceutical combination further contains a pharmaceutically acceptable excipient, and the pharmaceutically acceptable excipient does not have an adverse reaction with the A component and / or the B component.
[0031] In some embodiments of the present invention, the pharmaceutically acceptable excipients include fillers, disintegrants, binders, pH regulators and lubricants. The fillers include any one or more of starch, lactose, mannitol, dextrin, microcrystalline cellulose, and sucrose, preferably starch, sucrose, and dextrin. The disintegrants include any one or more of sodium carboxymethyl starch, hydroxypropyl cellulose, povidone, and sodium carboxymethyl cellulose, preferably sodium carboxymethyl starch. The binders include any one or more of starch slurry, powdered sugar, syrup, polyethylene glycol, methyl cellulose, ethyl cellulose, and hydroxypropyl methyl cellulose, preferably starch slurry. The pH regulator includes any one or more of triethanolamine, sodium hydroxide, magnesium sulfate, citric acid, tartaric acid, and lactic acid, preferably triethanolamine, citric acid, and lactic acid. The lubricant includes any one or more of magnesium stearate, talc, sodium laurel sulfate, magnesium laurel sulfate, and hydrogenated vegetable oil, preferably magnesium stearate and hydrogenated vegetable oil. In addition to those listed above, other suitable excipients may be selected according to actual needs, provided that the excipients do not react adversely with the component A and / or component B, and the amount of the excipients may also be determined according to techniques known in the art.
[0032] In some embodiments of the present invention, in the pharmaceutical composition, the component A and the component B are in separate preparations. When the pharmaceutical composition is a combination of two separate preparations comprising component A and component B, the component A and component B are administered simultaneously, or the component A and component B are administered in a certain order and at a certain time interval.
[0033] The second aspect of the present invention is to provide the use of the above-mentioned pharmaceutical composition in the preparation of drugs for inhibiting the growth and / or proliferation of tumor cells.
[0034] In some embodiments of the present invention, the tumor includes any one or more of breast cancer, gastric cancer, nasopharyngeal cancer, and ovarian cancer, preferably breast cancer.
[0035] The present invention also provides the use of the above-mentioned pharmaceutical composition in the preparation of anti-tumor drugs.
[0036] In some embodiments of the present invention, the tumor includes any one or more of breast cancer, gastric cancer, nasopharyngeal cancer, and ovarian cancer, preferably breast cancer.
[0037] Compared with the prior art, the present invention has the following beneficial effects:
[0038] In view of the problem that the existing technology cannot effectively control cancer using a single drug, the present invention creatively combines compound 1 and / or its derivatives with docetaxel and / or its derivatives for combined use. It is found that the combined use has a good synergistic effect and has a good inhibitory and synergistic effect on the growth of cancer cells, and is expected to be used in the combined treatment of cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 This is the relationship curve between HCC1187 inhibition rate and Hu7691 concentration.
[0040] Figure 2 This is the relationship curve between HCC1187 inhibition rate and DTX concentration. DETAILED DESCRIPTION
[0041] The present invention is further described in detail below by specific examples. Unless otherwise specified, the raw materials, reagents or devices used in the examples and comparative examples can be obtained from conventional commercial sources or can be obtained by prior art methods. Unless otherwise specified, the experiments or test methods are conventional methods in the art.
[0042] In the following examples, Hu7691 refers to DTX refers to docetaxel.
[0043] Example 1
[0044] HCC-1187 is a human breast ductal carcinoma cell line and one of the breast cancer cell lines commonly used to test the efficacy of compounds. The inhibitory effect of the compound on the HCC-1187 cell line can directly reflect its anti-breast cancer activity. Therefore, the following experiment of Hu7691 combined with DTX on HCC1187 tumor cells was used to study the therapeutic effect of combined drug therapy on breast cancer.
[0045] PBS solution preparation: Phosphate Buffered Saline
[0046] PBS 1L formula pH 7.4:
[0047] Potassium dihydrogen phosphate (KH2PO4): 0.24 g,
[0048] Disodium hydrogen phosphate (Na2HPO4): 1.44 g,
[0049] Sodium chloride (NaCl): 8g,
[0050] Potassium chloride (KCl): 0.2 g,
[0051] Add about 800 mL of deionized water and stir thoroughly to dissolve, then add concentrated hydrochloric acid to adjust the pH to 7.4, and finally adjust the volume to 1 L.
[0052] The HCC1187 tumor cell line was cultured in RPMI-1640, DMEM or other culture medium containing 10% fetal bovine serum in a 37° C., 5% CO 2 incubator or air culture box.
[0053] A 10 μM Hu7691 stock solution was prepared using PBS solution, and 10 Hu7691 solutions with a concentration gradient were obtained after three-fold dilution (10, 3.333, 1.111, 0.370, 0.123, 0.041, 0.014, 0.005, 0.002, 0 μM). In addition, a 1000 nM DTX stock solution was prepared using PBS solution, and 6 DTX solutions with a concentration gradient were obtained after gradient dilution (1000, 100, 10, 1, 0.1, 0 nM).
[0054] According to the laboratory background data, 15,000 units of HCC1187 tumor cells were inoculated in a 96-well transparent culture plate, and the cells were kept in the logarithmic growth phase throughout the experiment. Ten concentrations of Hu7691 solution and six concentrations of DTX solution were added to the 96-well transparent culture plate according to the orthogonal method. Each group of experiments was repeated 3 times.
[0055] After the drug and cells acted for 72 hours, the culture medium was discarded, and a pre-cooled 10% trichloroacetic acid (TCA) solution was added to each well to fix the cells, and the cells were placed in a 4°C refrigerator for fixation for 2 hours. The wells of the culture plate were washed 5 times with deionized water to remove the trichloroacetic acid solution. After drying, a 1% acetic acid-prepared SRB solution (4 mg / ml) was added to each well and placed at room temperature for 20 minutes. The liquid in each well was discarded and washed 5 times with 1% acetic acid. After washing away the unbound SRB dye, the wells were air-dried, and an appropriate volume of 10 mM Tris-base (trihydroxymethylaminomethane) solution was added to each well for dissolution. After complete dissolution, the absorbance OD value was measured at a wavelength of 515 nm using an enzyme reader, and the inhibition rate and IC of HC1187 were calculated. 50 The results are shown in Tables 1 to 3. The relationship curves between the inhibition rate and the concentrations of Hu7691 and DTX are shown in Figure 1 and 2 shown.
[0056] Table 1. Inhibition rate of Hu7691 combined with DTX on HCC1187 (%)
[0057]
[0058]
[0059] Table 2. IC of HCC1187 at different DTX concentrations 50 The corresponding Hu7691 concentration
[0060] DTX concentration (nM) <![CDATA[IC 50 Corresponding Hu7691 concentration (μM)]]> 0 >10 0.1 >10 1 1.3216 10 / 100 / 1000 /
[0061] Table 3. IC of HCC1187 at different Hu7691 concentrations 50 The corresponding DTX concentration
[0062] Hu7691 concentration (μM) <![CDATA[IC 50 Corresponding DTX concentration (nM)]]> 10 0.3621 3.333 0.7234 1.111 1.0001 0.370 1.1521 0.123 1.0790 0.0411 1.1615 0.014 1.2183 0.005 1.0158 0.002 1.1056 0 1.03715
[0063] The test results show that in the case of Hu7691 at a certain concentration, as the concentration of DTX increases, the inhibition rate of the combined drug on HC1187 shows an increasing trend, and the IC of DTX on HC1187 50 gradually decreases. At the same time, in the case of DTX at a certain concentration, as the concentration of Hu7691 increases, the inhibition rate of the combined drug on HC1187 also shows an increasing trend.
[0064] The combination index (CI value) of Hu7691 combined with DTX was calculated by the Chou-Talalay method. According to the CI value, the strength and nature of the interaction between Hu7691 and DTX were quantitatively judged (CI>1 is antagonistic effect, CI = 1 is additive effect, 0.7 < CI < 1 is slight synergistic effect, 0.3 < CI < 0.7 is synergistic effect, CI < 0.3 is strong synergistic effect). The results are shown in Table 4.
[0065] Table 4. CI values of Hu7691 combined with DTX
[0066]
[0067] From the above results, it can be seen that when the concentration of DTX is >100 nM, there is an antagonistic effect between Hu7691 at any concentration and DTX, and CI>6. When the concentration of DTX is 100 nM, there is a weak synergistic effect between Hu7691 at different concentrations and DTX, 0.7 < CI < 1. When the concentration of DTX is ≤10 nM, there is a good synergistic effect between Hu7691 and DTX.
[0068] The above embodiments are the preferred embodiments of the present invention, but the embodiments of the present invention are not limited by the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications made without departing from the spirit and principle of the present invention shall be equivalent replacement methods and are all included in the protection scope of the present invention.
Claims
1. A pharmaceutical composition, characterized in that: The pharmaceutical composition comprises a pharmaceutically active ingredient component A and a component B, wherein component A is compound 1 and / or its derivatives, wherein R 1 , R 2 and R 3 are independently selected from H, halogen, C 1-6 Alkyl, C 1-6 The B component is paclitaxel or its derivatives, docetaxel or its derivatives, or a combination of the two.
2. The pharmaceutical composition according to claim 1, characterized in that: The halogen is selected from F, Cl, Br, I; preferably F, Cl, Br; preferably, the C 1-6 The alkyl group is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl; preferably methyl, ethyl, propyl; most preferably methyl; preferably, the C 1-6 The haloalkyl group is selected from chloromethyl, 1-chloroethyl, 2-chloroethyl, and trifluoromethyl; preferably chloromethyl and trifluoromethyl; most preferably trifluoromethyl.
3. The pharmaceutical composition according to claim 1 or 2, characterized in that: The derivatives include any one or more of stereoisomers, solvates, metabolites, and pharmaceutically acceptable salts.
4. The pharmaceutical composition according to claim 3, characterized in that: The pharmaceutically acceptable salt of Compound 1 includes any one or more of its L-malate, citrate, phosphate, chloride, nitrate, and sulfate, preferably its L-malate.
5. The pharmaceutical composition according to any one of claims 1 to 4, characterized in that: In the pharmaceutical composition, component A is and / or its L-malate, component B is docetaxel.
6. The pharmaceutical composition according to any one of claims 1 to 4, characterized in that: The molar ratio of component A to component B is 0-10:0-1, preferably 0.001-10:0.001-0.1, and more preferably 0.002-10:0.01-0.1; Preferably, the molar ratio of the component A to the component B is 0.002-10:0.01-0.05, most preferably 0.002-10:0.
01.
7. The pharmaceutical composition according to any one of claims 1 to 4, characterized in that: The pharmaceutical composition also includes pharmaceutically acceptable excipients.
8. Use of the pharmaceutical composition according to any one of claims 1 to 7 in the preparation of a drug for inhibiting the growth and / or proliferation of tumor cells.
9. The use according to claim 8, characterized in that: The tumor includes any one or more of breast cancer, gastric cancer, nasopharyngeal cancer, and ovarian cancer, preferably breast cancer.
10. Use of the pharmaceutical composition according to any one of claims 1 to 7 in the preparation of anti-tumor drugs; preferably, the tumor comprises any one or more of breast cancer, gastric cancer, nasopharyngeal cancer, and ovarian cancer, more preferably breast cancer.
Citation Information
Patent Citations
Polyfluoro-substituted aryl biheterocyclic derivatives, pharmaceutical compositions containing same, and application of polyfluoro-substituted aryl biheterocyclic derivatives
CN108341801A
